At the end of 2015, CTTQ Pharmaceutical Group and J&J entered into license agreement for development and commercialization of one innovative drug for curative treatments of Hepatitis B.

J&J will carry out the global development, production, registration and commercialization of the product outside China. According to the agreement, J&J will pay a total amount of up to $253 million as upfront and milestone payments, plus royalties.